Sunshine Biopharma, Inc.

NasdaqCM:SBFM Stock Report

Market Cap: US$6.9m

Sunshine Biopharma Management

Management criteria checks 3/4

Sunshine Biopharma's CEO is Steve Slilaty, appointed in Oct 2009, has a tenure of 15.25 years. total yearly compensation is $640.00K, comprised of 59.1% salary and 40.9% bonuses, including company stock and options. directly owns 0.003% of the company’s shares, worth $211.02. The average tenure of the management team and the board of directors is 8.1 years and 3.3 years respectively.

Key information

Steve Slilaty

Chief executive officer

US$640.0k

Total compensation

CEO salary percentage59.1%
CEO tenure15.3yrs
CEO ownership0.003%
Management average tenure8.1yrs
Board average tenure3.3yrs

Recent management updates

Recent updates

Sunshine Biopharma, Inc.'s (NASDAQ:SBFM) 73% Dip In Price Shows Sentiment Is Matching Revenues

Mar 14
Sunshine Biopharma, Inc.'s (NASDAQ:SBFM) 73% Dip In Price Shows Sentiment Is Matching Revenues

Sunshine Biopharma, Inc.'s (NASDAQ:SBFM) Share Price Is Matching Sentiment Around Its Revenues

Jan 29
Sunshine Biopharma, Inc.'s (NASDAQ:SBFM) Share Price Is Matching Sentiment Around Its Revenues

Slammed 26% Sunshine Biopharma, Inc. (NASDAQ:SBFM) Screens Well Here But There Might Be A Catch

Sep 12
Slammed 26% Sunshine Biopharma, Inc. (NASDAQ:SBFM) Screens Well Here But There Might Be A Catch

Sunshine Biopharma acquires Nora Pharma for C$30M

Oct 20

We Think Sunshine Biopharma (NASDAQ:SBFM) Can Afford To Drive Business Growth

Aug 08
We Think Sunshine Biopharma (NASDAQ:SBFM) Can Afford To Drive Business Growth

Sunshine Biopharma reports 1H results

Aug 04

Sunshine Biopharma: Advancing Novel Cancer Therapies And Antiviral Drugs

Apr 17

CEO Compensation Analysis

How has Steve Slilaty's remuneration changed compared to Sunshine Biopharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$4m

Jun 30 2024n/an/a

-US$4m

Mar 31 2024n/an/a

-US$4m

Dec 31 2023US$640kUS$378k

-US$5m

Sep 30 2023n/an/a

-US$27m

Jun 30 2023n/an/a

-US$28m

Mar 31 2023n/an/a

-US$27m

Dec 31 2022US$430kUS$360k

-US$27m

Sep 30 2022n/an/a

-US$3m

Jun 30 2022n/an/a

-US$5m

Mar 31 2022n/an/a

-US$7m

Dec 31 2021US$462kUS$156k

-US$12m

Sep 30 2021n/an/a

-US$14m

Jun 30 2021n/an/a

-US$11m

Mar 31 2021n/an/a

-US$9m

Dec 31 2020US$227kUS$177k

-US$3m

Sep 30 2020n/an/a

-US$2m

Jun 30 2020n/an/a

-US$2m

Mar 31 2020n/an/a

-US$972k

Dec 31 2019US$96kUS$28k

-US$1m

Sep 30 2019n/an/a

-US$1m

Jun 30 2019n/an/a

-US$2m

Mar 31 2019n/an/a

-US$2m

Dec 31 2018US$285kUS$85k

-US$2m

Compensation vs Market: Steve's total compensation ($USD640.00K) is about average for companies of similar size in the US market ($USD642.68K).

Compensation vs Earnings: Steve's compensation has increased whilst the company is unprofitable.


CEO

Steve Slilaty (72 yo)

15.3yrs

Tenure

US$640,000

Compensation

Dr. Steve N. Slilaty, Ph.D. is CEO & Chairman of Sunshine Biopharma, Inc. from October 15, 2009 and serves as President. Dr. Slilaty joined the Sunshine Biopharma, Inc. on October 15, 2009. He serves as th...


Leadership Team

NamePositionTenureCompensationOwnership
Steve Slilaty
Chairman15.3yrsUS$640.00k0.0031%
$ 211.0
Camille Sebaaly
CFO & Secretary15.3yrsUS$695.00k0.0030%
$ 207.6
Abderrazzak Merzouki
Chief Science Officer & Directorless than a yearUS$340.00k0.0029%
$ 204.1
Malek Chamoun
Chief Development Officerless than a yearno data0.093%
$ 6.4k
Robert Ferreira
President of Sunshine Bio Investments Incno datano datano data

8.1yrs

Average Tenure

62yo

Average Age

Experienced Management: SBFM's management team is seasoned and experienced (8.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Steve Slilaty
Chairman15.3yrsUS$640.00k0.0031%
$ 211.0
Abderrazzak Merzouki
Chief Science Officer & Director8.9yrsUS$340.00k0.0029%
$ 204.1
David Natan
Independent Director2.9yrsUS$80.00kno data
Rabi Kiderchah
Independent Director3.3yrsUS$80.00k0.000050%
$ 3.5
Andrew Keller
Independent Director2.9yrsUS$80.00kno data

3.3yrs

Average Tenure

70yo

Average Age

Experienced Board: SBFM's board of directors are considered experienced (3.3 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/05 10:49
End of Day Share Price 2025/01/03 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sunshine Biopharma, Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David BoucheyAegis Capital Corporation